# Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer

Source: https://onco.cc/trials/nct07900165/  
OnCo record `nct07900165` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Varsetatug masetecan run by CytomX Therapeutics, not yet recruiting.

## Summary

Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer is a phase 1/2 interventional study registered as NCT07900165 by CytomX Therapeutics, with 368 participants planned, started 2026-12. Conditions recorded: Colo-rectal Cancer. Interventions recorded: varsetatug masetecan, bevacizumab + 5-FU + leucovorin and bevacizumab.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07900165
- Phase: 1/2
- Setting: A Trial of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Participants With Metastatic Colorectal Cancer
- Sponsor: CytomX Therapeutics
- Enrolled: 368

## Sources

- ClinicalTrials.gov NCT07900165: https://clinicaltrials.gov/study/NCT07900165

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Varsetatug masetecan](https://onco.cc/drugs/varsetatug-masetecan/)
- companies: [CytomX Therapeutics](https://onco.cc/companies/cytomx-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07900165.json